Research programme: cyclophilin inhibitors - ContraVir Pharmaceuticals

Drug Profile

Research programme: cyclophilin inhibitors - ContraVir Pharmaceuticals

Alternative Names: 440-02; CPI-431-32; NICAMs - ContraVir

Latest Information Update: 04 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Isotechnika Pharma
  • Developer Aurinia Pharmaceuticals; ContraVir Pharmaceuticals; National Institute of Allergy and Infectious Diseases
  • Class Antivirals; Ciclosporins; Cyclic peptides
  • Mechanism of Action Cyclophilin inhibitors; Sodium-bile acid cotransporter-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatitis B
  • Discontinued Neurological disorders; Reperfusion injury; Viral infections

Most Recent Events

  • 24 Oct 2017 Early research in Hepatitis D in USA (PO)
  • 17 Oct 2017 ContraVir Pharmaceuticals enters into collaboration with the Li Ka Shing Institute of Virology at University of Alberta to evaluate CRV 431 for Hepatitis B treatment
  • 21 Aug 2017 ContraVir has patent protection for cyclophilin inhibitors in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top